During the last three months, 10 analysts shared their evaluations of AbbVie (NYSE:ABBV), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 5 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 3 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $219.8, along with a high estimate of $250.00 and a low estimate of $194.00. Marking an increase of 1.52%, the current average surpasses the previous average price target of $216.50.
Breaking Down Analyst Ratings: A Detailed Examination
A...
Login or create a forever free account to read this news
Sign up/Log in
